INTRODUCTION
Acute myeloid leukemia (AML) is a malignant disease characterized by differentiation blockage and proliferation of clonal hematopoietic stem or progenitor cells (HSPCs), which rapidly lead to bone marrow (BM) failure and eventually to death, if left untreated. Even with optimal therapeutic approaches, including intensive chemotherapy and allogeneic hematopoietic stem cell (HSC) transplantation, only a minority of patients are cured. Thus, to design more effective therapeutic approaches and improve clinical outcome, it is critical to identify and pharmacologically target key molecular mechanisms that drive the pathogenesis of this disease.
During leukemogenesis, AML cells (or blasts) progressively occupy and likely alter the BM niche where normal HSCs reside. 1 Emerging evidence suggests that leukemia cells induce molecular changes in distinct hematopoietic and non-hematopoietic cell populations in the niche. These changes contribute to the transformation of the normal hematopoietic niche into a 'leukemia niche' that becomes permissive of leukemia growth and disrupts normal hematopoiesis. 2 In vivo perturbation of the murine BM microenvironment by deletion of the retinoic acid gamma receptor, retinoblastoma protein, Notch signaling or the microRNA (miRNA)-processing enzyme dicer has been shown to promote aberrant myeloproliferation. [3] [4] [5] [6] Similarly, forced expression of β-catenin-activating mutants in osteoblasts induces leukemia in mice. 7 Furthermore, leukemia cells reduce the niche's ability to retain HSCs and normal hematopoietic activity. [8] [9] [10] However, the fine mechanisms through which leukemia cells co-opt and modify the normal hematopoietic niche remain largely unknown.
Exosomes are small vesicles (30-200 nm) that are secreted by a wide variety of normal and malignant cells, 11 and are increasingly recognized as key mediators of cell-to-cell communication. 12, 13 Cancer-derived exosomes are capable of supporting cancer growth and disrupting homeostasis of healthy tissue. 11, [14] [15] [16] [17] [18] Exosomes released from chronic myeloid leukemia (CML) cells, for example, can stimulate BM stromal cells to produce IL-8, a cytokine that supports leukemia growth. 19 Exosomes secreted by AML cell lines and primary AML blasts enter stromal cells and modify their function to enhance leukemia growth. 20, 21 However, most of the exosome studies in hematological malignancies are based on in vitro experiments and the direct contributions of AMLderived exosomes to leukemogenesis remain to be fully elucidated in vivo.
Cell lines and patient samples AML cell lines (KG1A, MV411 and NB4; ATCC) were cultured in IMDM (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA, USA). AML patient and control samples (peripheral blood or BM) were obtained under a City of Hope-Institutional Review Board-approved protocol with informed consent from patients or healthy individuals (see Supplementary Table 1 for more information). BM CD34+ cells were enriched using human CD34+ microbeads kit (Miltenyi Biotec, Auburn, CA, USA).
Antibodies
Detail information on antibodies used is available in Supplementary  Table 3 .
Isolation, culture and analysis of mesenchymal stromal progenitors Tibias and femurs were excised from 8-to 12-week-old mice. After removing the muscle and connective tissue, the bones were crushed gently with mortar and pestle in PBS buffer. The crushed mass was washed with PBS to remove all the BM cells. The remaining bone fragments were incubated at 37°C with collagenase I (3 mg/ml; Sigma, St Louis, MO, USA) and gently agitated for 40 min. The digested bones were then filtered with a 40 μm strainer (BD Biosciences, San Jose, CA, USA), pelleted at 200 g at 4°C and resuspended in PBS. The marrow cells were collected and red blood cells were depleted with ACK lysis buffer. The cells were blocked with anti-CD16/32 antibody and stained with labeled monoclonal antibodies against CD45, CD31, Ter119, Sca1, CD146 and CD166 (Supplementary Figure 1d ). The stained cells were then sorted using a FACSAria III sorter (BD Biosciences). The purity of sorted cells was confirmed by FACS analysis to be 499%. Sorted stromal cells from control and AML cells/exosomes-treated mice were cultured in the MEMalpha medium (Gibco) containing 15% FBS at 37°C with 5% CO 2 . For mesenchymal stromal progenitor analysis, at least 3000 events per sample were collected within the CD45-Ter119-CD31-gate and analyzed using FlowJo software (FlowJo, Ashland, OR, USA).
Isolation and analysis of long-term HSCs
HSPCs were enriched from red blood cell-lysed BM cells using c-Kit microbeads kit (Miltenyi Biotec). The enriched HSPCs were then blocked with anti-CD16/32 antibody, stained with labeled antibodies against c-Kit, Sca1, CD150, CD48, CD135 and lineage markers (CD3, CD4, CD8, CD11b, B220, CD19, Gr1 and Ter119) and double-sorted using a FACSAria III to isolate long-term HSCs (LT-HSC) (Supplementary Figure 1c) . For LT-HSC analysis, at least 1000 events per sample were collected within the lin-Sca1 +c-Kit+ (LSK) gate and analyzed using FlowJo software (FlowJo).
LT-HSC and stromal cells in vitro co-culture assay Overall Stromal cell and AML cells/derived exosomes co-culture assay A total of 10 000 Sca1+ stromal cells were co-cultured with 10 000 AML cells per exosomes (derived from 5 × 10 6 cells). After 48-h culture, stromal cells were harvested and analyzed for mRNA levels of different nicheassociated genes.
Exosome isolation, characterization and labeling Culture media or FBS was centrifuged at 100 000 g for 10 h to remove bovine exosome contamination from FBS. Centrifuged media was filtered using a 0.2 μm filter to avoid the FBS exosomes pellet, then collected in a flask and used for culturing the cells.
For exosome isolation from leukemic and normal hematopoietic cells, AML cell lines were cultured directly with the centrifuged media. For normal hematopoietic cells or primary AML patient samples the media were supplemented with 2 ng/μl Human TPO and KITL (Peprotech). Supernatants were collected 48 h later, centrifuged at 800 g for 10 min at 4°C to remove whole cells, centrifuged again at 10 000 g for 10 min at 4°C to remove cellular debris and filtered through a 40-μm membrane, prior to exosome preparation by centrifugation at 100 000 g for 1 h. The exosome pellet was washed twice in a large volume of PBS (Supplementary Figure 2c) . Nanoparticle tracking analysis was used to determine exosome concentration. The plasma samples were diluted 1:10 and visualized on the NanoSight NS300 nanoparticles detector instrument (Malvern, Westborough, MA, USA). For exosome protein quantification, the exosome pellet was dissolved in RIPA buffer and quantified using BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). For western blot analysis of exosomes, anti-TSG101, anti-CD63 and anti-β-actin antibodies were used. For in vitro and in vivo exosome tracing, exosomes were labeled using CFSE (10 μM; Thermo Fisher Scientific) in PBS for 30 min at 37°C. Labeled exosomes were washed with PBS and centrifuged 100 000 g for 1 h to remove excess dyes.
Tissue section and immunofluorescence staining Freshly dissected long bones were fixed in 4% paraformaldehyde for 20 min at 4°C, then decalcified in 10% EDTA at 4°C for 7 days. The bones were then embedded in 10% gelatin in PBS, frozen on dry ice and stored at 
Bones were sectioned using the CryoJane taping system (Instrumedics, Ann Arbor, MI, USA). Sections were stained with Masson's trichrome. For immunofluorescence staining, sections were blocked with 1% BSA, then probed with primary antibody at 4°C overnight: anti-Sca1, anti-CD146, anti-MECA32 and/or anti-osteocalcin (OCN). After washing with PBS, the sections were probed with Alexa dye-conjugated antibodies, Invitrogen (Carlsbad, CA, USA) goat anti-rat-555 or anti-rat-488 and antirabbit-555, then washed and stained with DAPI and mounted in ProLong Gold anti-fade mounting media (Molecular Probe, Eugene, OR, USA). Sections were analyzed using an Olympus IBX81 microscope (Olympus, Waltham, MA, USA). Slides that passed this initial inspection were scanned using a Zeiss LSM 700 confocal microscope (Zeiss, Thornwood, NY, USA). Zen 2012 analysis software was used to create the maximum intensity projections of confocal z-stacks.
Micro-computed tomography examination
The bones were scanned using an Inveon CT scanner (Siemens, Malvern, PA, USA) under the following specifications: total rotation: 360; magnification: medium-high; binning: 1; transaxial CCD size: 1120 px; axial CCD size: 1408 px; pixel size: 13.60 μm; voltage: 80 kV; current: 500 μA; and exposure time: 4000 ms. The files were then reconstructed using COBRA with no downsampling. Inveon Bone Morphometry Tools (Siemens) were used to analyze the data.
Fluidigm dynamic array
RNA was extracted from 100 double-sorted stromal cells, reverse transcribed and amplified. The resulting amplified cDNAs were analyzed by qPCR using the Biomark Dynamic Array (Fluidigm, South San Francisco, CA, USA). We reviewed the amplification curves and CT data using the Biomark system software suite (Fluidigm). Delta CT values were calculated by subtracting the CT value for a particular gene from the paired β-actin CT value. Fold-change values were calculated in a linear scale based upon the least-squares mean. The TaqMan probes (Applied Biosystems, Carlsbad, CA, USA) used are listed in Supplementary Table 2. Quantitative real-time PCR RNA was extracted from sorted cells using the RNeasy RNA isolation kit (Qiagen, Germantown, MD, USA) and was reverse transcribed into cDNA using the Sensiscript RT kit (Qiagen). The cDNA was amplified for specific targets using TaqMan assays on a ViiA 7 Real-Time PCR System (Applied Biosystems). The thermal cycling parameters were 40 cycles of 95°C for 15 s and 60°C for 1 min. Data were analyzed using the ViiA 7 software (Applied Biosystems). The TaqMan probes used are listed in Supplementary Table 2.
In vitro lineage differentiation of stroma progenitors For osteoblast differentiation, freshly sorted Sca1+ cells were cultured in MEM-alpha medium containing 15% FBS with the addition of 10 mM glycerol phosphate, 50 μM ascorbate-2-phosphate and 10 − 7 M dexamethasone at 37°C with 2% O 2 conditions for 3 weeks. Chondrocyte and adipocyte differentiation were performed using the StemXVivo system (R&D Systems, Minneapolis, MN, USA). Recombinant mouse DKK1 was obtained from R&D systems. DKK1 inhibitor Way-262611 was purchased from Axon Medchem (Reston, VA, USA).
LSK and LT-HSC cell cycle analysis
For cell cycle analysis, double-sorted LSK and LT-HSC cells were fixed in 2% formaldehyde and permeablilized in 70% methanol. Cells were stained with FITC-labeled anti-mouse Ki67 and propidium iodide (Invitrogen). The cutoff range for fluorescence was determined by a negative control sample stained with FITC-labeled isotype control Ig. At least 500 cells per sample were examined for each specimen and analyzed using FlowJo software (FlowJo).
Lentiviral shRNA transduction
Active lentiviral stocks were generated using human Rab27a-specific shRNA constructs (GE Dharmacon, Lafayette, CO, USA; clone ID: V3THS_300918) and control scrambled GFP vector, and used to transduce MV411 cells for exosome release inhibition. The transduced GFP-positive cells were analyzed for Rab27a mRNA expression levels using qPCR to confirm the knockdown.
OCN ELISA
Plasma OCN levels were determined using Quantikine ELISA kit (R&D systems). Frozen plasma samples from AML patients and healthy age-matched individuals were thawed and quantified in duplicate at 450 nm wavelength.
Statistical analysis
Statistical analyses were performed using Prism software v.7 (GraphPad, La Jolla, CA, USA). All data are presented as mean ± s.d. Two group comparisons were performed with a two-tailed Student's t-test; multiple group comparisons were performed with a one-way ANOVA test with multiple comparison option. For Kaplan-Meier survival curve analysis, the comparisons were performed using a log-rank test. A value of Po0.05 was taken as statistically significant. No statistical test was used to determine the sample size. No randomization was used to allocate animals to particular groups; age and sex-matched recipients were used for transplantation experiments. The investigator was not blinded to experimental groups during analysis.
RESULTS
AML engraftment alters bone architecture and cellular composition of the BM microenvironment To assess AML-induced changes in the BM microenvironment, we first injected human AML cells intrahepatically into newborn (2-3 days old) irradiated immunodeficient RAG2 22 This approach allows for a rapid generation of in vivo AML models to study the interplay of AML blasts and the BM niche in B6 genetic background mice, the main strain used for BM niche component analyses. For these experiments, we injected human primary AML blasts (isolated from AML patients seen at our institution, COH101 or COH103) or cell lines representative of relatively common genetic mutations occurring in human AML: MV411 (FLT3-ITD), KG1A (p53-null) or NB4 (PML-RARα). To confirm our results, we also engrafted AML blasts from the MLL-AF9 knockin AML mouse model 23, 24 into 8-week-old irradiated syngeneic recipients. Irradiated, age-matched, vehicle-injected mice or normal human CD34+ BM-injected served as controls. In this series of experiments, mice were killed 3-6 weeks after cell injections, upon evidence of leukemia development, or earlier if the animal was moribund.
All AML recipient mice developed leukemia and exhibited splenomegaly, compared with vehicle-or normal human CD34+ BM-injected controls ( Figure 1a Figure 1f) .
To analyze the non-hematopoietic compartments of the BM niche, we then enzymatically dissociated bone and marrow and isolated the stromal fraction based on surface markers (CD45 − Ter119 − CD31 − ). The stromal fraction was further divided based on CD146, CD166 and Sca1 expression into CD146+CD166 − immature osteoprogenitors (CD146+); CD146 − CD166+ osteoblasts (CD166+); and CD146 − CD166 − Sca1+ primitive stromal cells with the ability to differentiate into CD146+, CD166+ or CXCl12-abundant reticular (CAR) cells (Sca1+; Supplementary  Figure 1g) . 25 FACS analyses revealed that Sca1+ and CD146+ cells were significantly increased, and CD166+ cells were significantly decreased, in all models of AML-engrafted mice, compared with vehicle-injected controls (Figure 1c; Supplementary Figure 1h) . In contrast, the numbers of CD166+, CD146+ and Sca1+, cells were not significantly changed in mice engrafted with normal human CD34+ cells, compared with vehicle-injected controls (Supplementary Figure 1i) .
Histological analysis and immunofluorescence staining of bone sections with anti-OCN antibody confirmed the loss or thinning of the osteoblast layer in AML-engrafted animals, but not in vehicleinjected controls (Figures 1d and e) . Immunofluorescence staining of bone sections with anti-Sca1 and anti-CD146 antibodies confirmed the increase of Sca1+ and CD146+ cells (Figure 1e;  Supplementary Figure 1j) . The number of Sca1+ and CD146+ stromal cells located below the growth plate of the sectioned femurs was also significantly increased in AML-engrafted mice compared with controls (Sca1+: 22.25 vs 7.75 cells per 66 mm 2 , P = 0.0001; CD146+: 6.44 vs 3.50 cells per 102 mm 2 , P = 0.041; Figure 1e ; Supplementary Figure 1j) . Furthermore, microcomputed tomography (μ-CT) examination showed that cortical wall thickness, as well as trabecular bone volume, decreased in leukemic animals (Figure 1g ). Decreased trabecular bone volume resulted in a larger trabecular area in leukemic animals (Figures 1f  and g ). These data corroborate our FACS stromal compartment analysis (Figure 1c; Supplementary Figure 1h) and together support the notion that AML growth modifies the cellular composition of both the hematopoietic and non-hematopoietic compartments in the BM niche.
AML-derived exosomes target stromal and endothelial cells in the BM niche Exosomes are increasingly recognized as key mediators of cell-tocell communication and are aberrantly increased in certain types of cancer. 12, 13, 26 To determine whether circulating exosomes were increased in AML patients, we analyzed plasma samples from 43 de novo or secondary AML patients seen at our institution (COH107-COH191; Supplementary Table 1) . Using nanoparticle tracking analysis, 27 we found that plasma exosomes were significantly increased in AML patients (n = 43) compared with healthy controls (n = 12; 4.0 vs 1.6 × 10 9 /ml, P = 0.0016; Figure 2a ). Of note, consistent with our observation that osteoblast activities were reduced in AML-engrafted mice (Figure 1 ), we found significantly lower plasma levels of OCN, an indicator of bone formation activity, in AML patients than in healthy controls (17.3 vs 6.9 ng/ml, P o0.0001; Figure 2a ). Exosome counts were also significantly higher in patients with lower OCN levels (o 10 ng/ml) compared to those with higher OCN levels (410 ng/ml, Figure 2b ). These changes were not specific to the FLT3-ITD mutation or risk stratification in the analyzed AML blasts (Supplementary Figures 2a and b) .
Thus, we hypothesized that AML cells remodel the BM microenvironment partly through exosome secretion. To test this hypothesis, exosomes were prepared from the supernatant fractions of normal human peripheral blood mononuclear cell (PBMC) or AML cell culture by filtration and high-speed centrifugation 28 ( Supplementary Figure 2c) . The purity of the prepared exosomes were then assessed by nanoparticle tracking analysis ( Supplementary Figures 2d and e) and the exosome presence was confirmed by western blotting for the exosome markers CD63 and Tsg101 (Supplementary Figure 2f) and by electron microscopy, which documented vesicles of 30-100 nm in diameter ( Supplementary Figures 2g and h ), consistent with previous reports. 13 We labeled the exosomes with the fluorescent dye CFSE and incubated them with whole BM freshly isolated from a wild-type B6 mouse (Figures 2c and d) . Internalization of the labeled exosomes into mouse BM cells was demonstrated after 4 h (Figure 2c ). FACS analysis revealed that the exosomes were primarily internalized in the BM stromal (CD45 − Ter119 − CD31 − ) and endothelial (CD45 − Ter119 − CD31+) fractions. In contrast, few exosomes were internalized in the hematopoietic (CD45 +/Ter119+) fraction, except for a small subset of monocytes (CD11b+Gr1 − ; Figure 2d ). Next, we injected CFSE-labeled exosomes intravenously into B6 mice and harvested their BM cells 10 h later. Again, internalized exosomes were found mainly in the BM stromal and endothelial fractions ( Supplementary  Figure 2i) , suggesting that these cell populations are indeed the preferential BM targets for AML-derived exosome. (Figure 2e) .
AML-derived exosomes
Animals that received AML-derived exosomes showed changes similar to those observed in mice engrafted with AML cells, compared with controls treated with normal PBMC-derived exosomes, including enlarged spleens (Figure 2f ; Supplementary  Figure 3a) and increased endogenous BM LT-HSC (Figure 2g ; Supplementary Figures 3b and c ) . Like in AML-engrafted mice, FACS analysis showed Sca1+ and CD146+ stromal cells were significantly increased and CD166+ cells were significantly decreased in mice treated with AML-derived exosomes, compared with PBMC-derived exosome-treated controls, suggesting a block in osteoblast differentiation (Figure 2h ). Quantitative μ-CT analysis demonstrated loss of trabecular and cortical bone in the femurs of mice treated with AML-derived exosomes, compared with PBMCderived exosome-treated controls (Supplementary Figure 3d) . In vivo PBMC-derived exosome treatment did not induce significant changes in the stromal compartments compared with vehicleinjected controls (Supplementary Figure 3e) .
Next, we focused on AML-induced gene expression changes in the BM stromal compartment. Sca1+, CD146+ and CD166+ stromal cells from DKO mice engrafted with AML cell lines (MV411 and KG1A) or primary patients' blasts (COH101 and COH105) were sorted and analyzed for expression levels of hematopoiesis-and osteogenesis-related genes. Genes that modulate normal hematopoiesis (IGF1, CXCL12, KITL and IL-7) or are implicated in bone development (IGF1, OCN and Col1A1) were downregulated, whereas a suppressor of normal hematopoiesis and osteoblast development (DKK1), 29 was upregulated in stromal cells from AML-engrafted vs vehicle-injected control animals (Supplementary Figure 4a) . Despite some variations among cell lines and primary samples, a similar trend was observed in all models. These results further validate the observation that osteoblast maturation is disrupted in AMLengrafted mice (Figures 1e-j) . Importantly, similar trends of gene expression were also observed in Sca1+, CD146+ and CD166+ stromal cells isolated from mice treated with AML-derived exosomes (Figure 3a) .
To validate these results, we treated ex vivo Sca1+, CD146+ and CD166+ cells from B6 mice with AML-derived exosomes. We observed similar downregulation of OCN, Col1A1 and IGF1 as seen in AML-engrafted mice. However, no significant changes were observed in KITL and CXCL12 expression, except for CXCL12 downregulation in CD146+ cells (Supplementary Figure 4b) . Levels of genes encoding pro-inflammatory cytokines (that is, IL-6 and CCL3) were also significantly increased in AML exosome-treated CD146+ and CD166+ cells (Supplementary Figure 4b) , but not in the stromal cells from leukemic or AML exosome-treated mice (data not shown). Differences between in vivo and ex vivo environments, dosage of AML-derived exosomes (four vs one doses) and time after initial treatments with exosomes (48 h vs 30 days) may account for the differences in outcomes. Similar Figures 5c and d) .
As DKK1, a potent negative regulator of osteoblast development, was overexpressed in the BM niche of AML-engrafted and AML-derived exosome-treated mice (Figure 3a ; Supplementary  Figure 4a ), we hypothesized that elevated levels of DKK1 may explain the limited osteoblast differentiation seen in the Sca1+ cells from those mice. To test this hypothesis, we cultured ex vivo Sca1+, CD146+ and CD166+ cells from B6 mice with AML-derived or PBMC-derived exosomes. DKK1 expression was upregulated in all BM stromal cells treated with AML-derived exosomes compared to PMBC-derived exosomes (Sca1+: 15.69-fold, P o0.0001; CD146 +: 3.8-fold, P = 0.0282; CD166+: 11.04-fold, P o 0.0001; Supplementary Figure 5e) .
Furthermore, Sca1+ cells isolated from B6 mice and cultured under osteogenic conditions with 10 ng/ml of recombinant DKK1 showed no ability to differentiate into osteoblasts ( Supplementary  Figures 5f and g ). To evaluate the ability of DKK1 inhibition to rescue the changes induced by AML cells or AML-derived exosomes, we treated Sca1+ cells from B6 mice with AMLderived or PBMC-derived exosomes in the presence or absence of the DKK1 inhibitor Way-262611 for 20 h. The treated cells were then cultured under osteogenic conditions for 21 days. Osteoblast differentiation was not changed by DKK1 inhibitor in PBMC-exosome-treated Sca1+ cells (OCN: 1.29 vs 0.95-fold, P = 0.1546). In contrast, DKK1 inhibitor rescued the decreased osteoblast differentiation induced by AML-derived exosome (OCN: 1.14 vs 0.3-fold, P = 0.0018; Figure 3d ; Supplementary Figure 5h) .
Next, we hypothesized that reversal of the effects of AML cells and AML exosomes on BM niche by in vivo DKK1 inhibition may delay AML progression. Eight-to ten-week-old NSG mice were engrafted with 1 million MV411 AML cells and received four intraperitoneal doses of DKK1 inhibitor (35 mg/kg body weight) or DMSO (vehicle control) pre-engraftment, and one dose postengraftment. Mice engrafted with AML cells and treated with DKK1 inhibitor survived significantly longer than mice engrafted with AML cells but treated with vehicle only (median survival: 64 vs 50 days, P = 0.0067; Figure 3e ), suggesting that AML engraftment-or AML-derived exosome-induced DKK1 expression likely suppressed osteoblast differentiation and supported enhanced leukemia growth.
AML-modified stromal cells exhibit reduced ability to support normal hematopoiesis and enhance leukemia growth One relatively unexpected finding in mice engrafted with AML cells or treated with AML-derived exosomes was the increased percentage of endogenous LT-HSCs (Figures 1b and 2g ; Supplementary Figures 3b and c) . Thus, we asked whether these LT-HCSs were functionally equivalent to those that support normal hematopoiesis in normal mice. We compared the cell cycle of LT-HSCs from B6 mice treated with AML-derived exosomes with LT-HSCs from mice treated with PBMC-derived exosomes ( Supplementary Figures 6a and b) . In LT-HSCs from mice treated with AML-derived exosomes, a reduced percentage of cells were in G0 phase (Supplementary Figure 6c) , whereas an increased percentage of cells were in S/G2/M phase ( Supplementary  Figure 6d) , compared with LT-HSCs from mice treated with PBMC-derived exosomes.
To assess the hematopoietic repopulating activity in mice treated with AML-derived exosomes, we transplanted whole BM cells from exosome-treated B6-45.1 mice into irradiated B6 (45.2) congenic mice. Mice transplanted with whole BM cells from donors treated with AML (KG1A)-derived exosomes showed lower blood and BM engraftment at 22 weeks after transplant, compared to controls transplanted with whole BM cells from mice treated with PBMC-derived exosomes (Figure 4a ). In addition, we used the S phase-specific cytotoxic chemotherapeutic agent 5-fluorouracil (5-FU) to induce myeloablative stress. Mice were treated with three weekly doses of AML-or PBMC-derived exosomes, before receiving weekly injections of 5-FU (150 mg/ Figure 2 . AML-derived exosomes are elevated and associated with reduced OCN levels in AML patients, are internalized by BM cells, induce splenomegaly, increase LT-HSC population and alter stromal compartment in the BM microenvironment. (a) Plasma exosome numbers measured by NanoSight (left) and plasma OCN levels were determined by ELISA (right) in healthy control (n = 12) and AML patients (n = 43). (b) Plasma exosome count in AML patients with low ( o 10 ng/ml, n = 29) or high (410ng/ml, n = 14) plasma OCN levels. (c) Overall, 100 μg CFSE-labeled exosomes were co-cultured with BM cells for 4 h. Uptake of CFSE-labeled exosomes by marrow cells was analyzed by fluorescence microscopy. (d) Uptake of CFSE-labeled exosomes by marrow cells was analyzed by FACS analysis for internalization of CFSElabeled exosomes in indicated BM subpopulations (left). Percent CSFE+ cells within indicated BM subpopulations were summarized (right, n = 3 mice in three independent experiments). (e) Six-to eight-week-old B6 mice were injected with either normal human PBMC-derived or AML-derived exosomes. Mice were euthanized 30 days after initial injection. (f) Mouse spleen is weight is summarized (n = 5-6 mice per group in at least two independent experiments). (g) Frequency of LT-HSC in BM (n = 6-8 mice per group in at least three independent experiments). (h) Frequency of Sca1+, CD146+ and CD166+ cells in the stromal compartment (n = 6-8 mice per group in at least three independent experiments). ns, not significant, *P o0.05, **P o0.01, ***P o0.001, ****P o0.0001. kg body weight) until death (Supplementary Figure 6e) . AMLderived exosome-treated mice showed reduced survival compared with PBMC-derived exosome-treated mice (median survival: 12.5 vs 15.5 days, P = 0.0005; Supplementary Figure 6f) , thereby indicating a compromised hematopoietic recovery after myeloablative stress.
Exosomes
Stromal To determine whether AML cells or AML-derived exosomes functionally altered the BM niche's ability to support normal HSCs, we incubated sorted Sca1+ stromal cells from B6 mice with KG1A and NB4 cells, primary AML patient blasts (COH101), or AML-or PBMC-derived exosomes for 2 days, followed by co-culture with LT-HSCs from B6-45.1 mice for 2 additional days. These LT-HSCs were then transplanted into B6 congenic recipients and hematopoietic activity of the grafts was evaluated (Figure 4b ). Mice receiving LT-HSCs co-cultured with AML-treated or AML-derived exosome-treated Sca1+ cells showed a significantly decreased engraftment rate at 16 weeks post-transplantation, compared with controls that received LT-HSCs co-cultured with PBMC-derived exosome-treated or untreated Sca1+ cells (CD45.1: 4.84 vs 17.82 or 19.94% engraftment, Po 0.0001; Figure 4b ).
Next, we asked whether preconditioning the BM niche using AML-derived exosomes could facilitate AML growth. Mice pretreated with weekly doses of AML-derived exosomes for 3 weeks were then injected with KG1A cells and analyzed for leukemia engraftment. These mice showed a significantly higher rate of leukemia cell engraftment at 20 days (human CD45+: 13.17 vs 1.1 or 1.08% engraftment, P = 0.0486 or 0.0363) and a shorter survival than controls pretreated with weekly doses of PBMCderived exosomes or vehicle before transplant (median survival: 22.5 vs 30 or 35 days, P = 0.0083 or 0.0075; Figure 4c ). FACS analysis of the stromal compartment showed that populations of Sca1+ and CD146+ stromal cells significantly increased (Sca1+: 4.32 vs 3.17% of total stromal cells, P = 0.0113; CD146+: 4.26 vs 3.03% of total stromal cells, P = 0.0166) and CD166+ stromal cells significantly decreased (1.91 vs 2.44% of total stromal cells, P = 0.0276) in mice that received AML-derived exosomes, compared with mice that received PBMC-derived exosomes (Supplementary Figure 7a) .
To test whether AML-derived exosomes are required for leukemia growth, we reduced exosome secretion in AML cells. We used a lentiviral shRNA construct to knockdown Rab27a, a protein implicated in the exosome release process, 30 in MV411 AML cells. Exosome secretion was significantly reduced in Rab27a-knockdown cells compared with scrambled shRNA controls (Figure 4d ), without any significant changes in the cell cycle (Supplementary Figure 7b) or baseline apoptosis ( Supplementary  Figure 7c) of the transduced cells. Two million Rab27a-knockdown or scrambled control AML cells were then intrahepatically injected into 2-to 3-day-old DKO mice. The mice that received shRab27a-knockdown AML cells survived longer than mice that received scrambled control AML cells (median survival: 28.5 vs 24 days, P = 0.0016; Figure 4d ), indicating that reduced exosome secretion in AML cells delayed AML growth.
DISCUSSION
The functional relevance of cancer-derived exosomes to tumor growth, metastasis and treatment response has become increasingly evident. [16] [17] [18] 31 Using a combination of in vivo and in vitro approaches, we demonstrate here that AML-derived exosomes are important for transforming the composition and function of the BM niche. Treatment with exosomes derived from a variety of human and mouse AML cells recapitulates changes similar to those observed in mice engrafted with AML cells. Specifically, AML-derived exosomes preferentially target BM stromal and endothelial cells and alter the differentiation potential of mesenchymal progenitors, thereby decreasing osteoblast development. Histologically, these cellular changes result in reduced cortical bone wall thickness and decreased trabecular bone volume and trabeculation. In line with these results, we showed decreased plasma levels of OCN in AML patients. Furthermore, as in AML engraftment experiments, treatment of BM stromal cells with AML-derived exosomes decreases the expression of genes supporting normal hematopoiesis (CXCL12, KITL, IL-7, IGF1) and osteogenesis (OCN, Col1A1, IGF1) and increases expression of genes supporting AML growth (DKK1, IL-6, CCL3). Preconditioning BM with AML-derived exosomes accelerates AML cell engraftment and growth, whereas disruption of exosome secretion in AML cells significantly decreases the ability of these cells to engraft and grow in vivo. Similar to the effect of AML engraftment, treatment with AML-derived exosomes also increases the fraction of normal LT-HSC engaged in cell cycling, and impairs normal hematopoietic reconstitution. Our findings, therefore, indicate that AML cells induce exosome-dependent cellular changes in the hematopoietic and non-hematopoietic compartments of the BM niche that lead to attenuation of normal hematopoiesis while enhancing leukemia growth. Our observations are supported by previous studies that suggest tumor-derived exosomes are key players in vascular leakiness and stromal cell education at metastatic sites. 17, 32 The role that AML cells and AML-derived exosomes have in decreasing osteoblast differentiation is particularly intriguing to us, as it may be pharmacologically targetable. Consistent with our data, a recent study indicated suppression of the osteoblast population and osteoblast-associated gene signature through aberrant Notch signaling occurs in acute lymphoblastic leukemia. 33 Our findings are also consistent with previous reports demonstrating severe osteoblastic defects in AML mouse models, 34 and in AML and MDS patients. 35 Genetic ablation of osteoblasts in AML or CML mice was correlated with increased progression of leukemia, 35, 36 whereas treatment of AML mice with compounds capable of inhibiting osteoblast loss decreased tumor burden and prolonged survival. 35 Hanoun et al. 24 reported a similar blockade of osteoblastic differentiation in an MLL-AF9 AML model, which was associated with neuropathic damage in the BM. In contrast, increased trabeculation, trabecular thickening and a massive expansion in osteoblast lineage cells have been observed in a myeloproliferative neoplasm model. 9 Krause et al. 23 found that activating the parathyroid hormone receptor in osteoblasts caused opposite effects in CML and AML models, with decreased disease for CML mice and increased disease in AML mice. Thus, it is possible that the BM niche is affected differently in distinct types of hematologic malignancies. Although there are only limited reports that adult patients with AML have osteopenia and osteoporosis before allogeneic BM transplantation, 37 it is known that bone loss and increased fracture risk are common complications for AML patient after transplantation. 38, 39 Mesenchymal progenitors reprogrammed by AML-derived exosomes may contribute to observed bone defects in these patients. Mitigation of osteolineage differentiation defects may provide a novel therapeutic strategy to accelerate patient recovery. More studies are required to determine the exact clinical relevance of our observation. Gene expression analysis indicates that DKK1, an osteoblast inhibitor and a negative regulator of Wnt signaling that is central to both hematopoiesis and bone development, 40 is upregulated in our AML and AML-exosome models. Forced overexpression of DKK1 in osteoblasts results in a phenotype similar to what we observed in AML-engrafted and AML-derived exosome-treated mice-blockage of osteolineage development, disruption of the BM niche and defects in HSC function. 41 Using a lineage differentiation assay, we demonstrated that mesenchymal stromal progenitors treated with AML-derived exosomes or from AML mice have an increased adipogenic and decreased osteogenic and chondrogenic differentiation ability. Treatment with DKK1 inhibitors reverses the effect of AML exosomes on stromal lineage differentiation. These findings are in line with previous reports that DKK1 can induce mesenchymal stromal cell proliferation and switch their differentiation pathway from osteogenesis to adipogenesis. [42] [43] [44] [45] [46] Moreover, elevated DKK1 levels were also implicated in causing osteolytic phenotypes in multiple myeloma and metastatic breast cancer. 29, [47] [48] [49] As Wnt signaling is activated in AML, this may raise concerns that targeting DKK1 overexpression could lead to hyper-activation of the Wnt pathway and enhanced leukemia growth. [50] [51] [52] However, our results also indicated that in vivo DKK1 inhibition significantly delays AML progression, rather than accelerates leukemia growth. It was suggested that although AML cells themselves have an endogenous aberrant Wnt activation, they may not be as dependent as normal HSCs on niche-derived Wnt signaling. 51 Further studies are required to fully understand the interplay between DKK1 and Wnt signaling in the leukemic niche. Altogether, our results suggest that the elevated DKK1 levels induced by AML-derived exosomes are part of the mechanism employed by AML to alter the lineage potential of BM stromal progenitors and provide a competitive advantage to leukemia cells during AML development. Thus, DKK1 may be a potential new therapeutic target.
Our finding that treating mesenchymal stromal progenitors with AML-derived exosomes increased their adipogenic ability suggests exosome targeted skeletal sites may have increased marrow fat content, which has been associated with enhanced cancer resistance to systemic chemotherapy and radiation. 53 Ye et al. 54 also indicated that leukemia cells can co-opt adipose tissue to support their metabolism and survival. Recent technology advances have enabled us to simultaneously determine the sitespecific marrow fat content, osteoblastic activity and hematopoiesis. 55, 56 Improved understanding of bone and marrow composition changes in AML patients may lead to improved therapeutic options.
Altogether, our data support the notion that AML cells remodel the BM niche through exosome secretion, to favor leukemic cell proliferation and survival, whereas suppressing normal hematopoiesis. Although current studies suggest that treatment with certain drugs can reverse the damage caused to the niche by leukemia cells, 8 to date, treatments for AML have mainly focused on eradication of leukemia cells, with little consideration that repairing a leukemia-damaged BM niche and eliminating a fertile ground for disease recurrence may be equally important. Thus, novel therapeutic strategies that restore a BM niche that can adequately support normal hematopoiesis over leukemogenesis should be developed. Disrupting exosome production and/or secretion in AML cells or directly targeting factors induced by AML-derived exosomes, such as DKK1, may provide new avenues to prevent AML-induced transformations of BM niche, and enhance the anti-leukemia activity of emerging molecularlytargeted compounds for AML patients. . AML-derived exosomes reduce stem cell activities, limit ability of stroma to support normal HSCs and accelerate AML progression; disruption of exosome production delays AML progression. (a) Repopulation ability of marrow from normal PBMC-derived or AML (KG1A)-derived exosome-treated donors was assayed 22 weeks after transplantation into congenic recipients (n = 5-6 mice per group in two independent experiments). (b) CD45.1 HSCs were co-cultured with the AML cell/exosome-modified stroma for 48 h and transplanted (100 per mouse) into lethally irradiated WT CD45.2 recipients along with 200 000 unfractionated CD45.2 helper BM cells. Ability of control and AML cell/exosome co-cultured HSCs to repopulate the blood of recipient mice was assayed 19 weeks after transplantation (n = 6-8 mice per group in three independent experiments). (c) Three weekly doses of AML-derived or normal PBMC-derived exosomes, or PBS vehicle control, were injected intravenously into 6-to 8-week-old DKO mice. Mice were irradiated and injected with 20 million KG1A cells. AML cell engraftment in peripheral blood was assayed 20 days later (middle). Kaplan-Meier survival analysis of control or treated mice (right; n = 8-13 mice in at least two independent experiments). (d) MV411 AML cells were transduced with lentiviral shRNA against Rab27a, a protein involved in exosome release. qRT-PCR of Rab27a levels (left) and total exosome protein quantification (middle). Kaplan-Meier survival curve for mice transplanted with lentiviral shRab27a-transduced MV411 cells (right; n = 8-10 mice in two independent experiments). ns, not significant, *Po 0.05, **P o0.01, ***P o0.001.
